Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

doi:10.1016/j.clgc.2018.01.013

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Clinical genitourinary cancer - 1 Aug 2018

Verbiest Annelies, Lambrechts Diether, Van Brussel Thomas, Couchy Gabrielle, Wozniak Agnieszka, Méjean Arnaud, Lerut Evelyne, Oudard Stéphane, Verkarre Virginie, Job Sylvie, de Reynies Aurélien, Machiels Jean-Pascal, Patard Jean-Jacques, Zucman-Rossi Jessica, Beuselinck Benoit

Abstract excerpt

BACKGROUND: Clear-cell renal-cell carcinoma (ccRCC) is characterized by loss of a functional Von Hippel-Lindau (VHL) protein. We investigated the potential of 3 single nucleotide polymorphisms (SNPs) in VHL as biomarkers in metastatic ccRCC (m-ccRCC) patients treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: We genotyped 3 VHL SNPs in 199...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Dedifferentiation

Share to Kidney Neoplasms

Share to Loss of Heterozygosity

Share to Pharmacogenomic Variants

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed

Identifiers

PMID: 29503246
DOI: 10.1016/j.clgc.2018.01.013

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.PMID 29503246Read ↗

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.Semantic proximity Read ↗

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.Semantic proximity Read ↗

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.Semantic proximity Read ↗

Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinomaSemantic proximity Read ↗

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review.Semantic proximity Read ↗

Does the VHL polymorphisms rs779805 and rs1642742 affect renal cell carcinoma susceptibility, prognosis and survival in Central European population?Semantic proximity Read ↗

Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.Semantic proximity Read ↗

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.Semantic proximity Read ↗

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic responseSemantic proximity Read ↗

VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.